Exenatide reduces urinary transforming growth factor-β1 and type IV collagen excretion in patients with type 2 diabetes and microalbuminuria

Kidney and Blood Pressure Research

Volumn 35, Issue 6, 2013, Pages 483-488

  Zhang, Hong ^a   Zhang, Xiangcheng ^a   Hu, Changjun ^a   Lu, Weiping ^a  

^a THE AFFILIATED HUAIAN NO 1 PEOPLE S HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Exenatide; Transforming growth factor 1; Type IV collagen; Urinary biomarkers

Indexed keywords

ALBUMIN; COLLAGEN TYPE 4; EXENDIN 4; GLIMEPIRIDE; HEMOGLOBIN A1C; METFORMIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG DOSE INCREASE; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; MALE; MICROALBUMINURIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL PROTECTION; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; URINARY EXCRETION; VOMITING;

ADULT; AGED; ALBUMINURIA; BIOLOGICAL MARKERS; COLLAGEN TYPE IV; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PEPTIDES; TRANSFORMING GROWTH FACTOR BETA1; VENOMS;

EID: 84861972909     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000337929     Document Type: Article

References (25)

1. Stamm C, Burnier M, Zanchi A: Diabetes and end stage renal disease. Eight year progression in the Canton de Vaud, Switzerland. Rev Med Suisse 2011; 7: 495-499.
2. Yang W, Lu J, Weng J, Jia W, Ji L, Xiao J, Shan Z, Liu J, Tian H, Ji Q, Zhu D, Ge J, Lin L, Chen L, Guo X, Zhao Z, Li Q, Zhou Z, Shan G, He J, China National Diabetes and Metabolic Disorders Study Group: Prevalence of diabetes among men and women in China. N Engl J Med 2010; 362: 1090-1101.
3. Lawal M: Management of diabetes mellitus in clinical practice. Br J Nurs 2008; 17: 1106-1113.
4. Agarwal R: Anti-inflammatory effects of short-term pioglitazone therapy in men with advanced diabetic nephropathy. Am J Physiol Renal Physiol 2006; 290:F600-F605.
5. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D: Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post-hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007; 18: 1540-1546.
6. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators: Effects of losar tan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
7. Metwally SS, Mosaad YM, Nassr AA, Zaki OM: Transforming growth factor- 1 in diabetic nephropathy. Egypt J Immunol 2005; 12: 103-112.
8. Ziyadeh FN: Mediators of diabetic renal disease: The case for TGF - as the major mediator. J Am Soc Nephrol 2004; 15(suppl):S55-S57.
9. Thorens B: Expression cloning of the pancreatic - cell receptor for the gluco-incretin hormone glucagon-like peptide 1. Proc Natl Acad Sci USA 1992; 89: 8641-8645.
10. Bullock BP, Heller RS, Habener JF: Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137: 2968-2978.
11. Kodera R, Shikata K, Kataoka HU, Takatsuka T, Miyamoto S, Sasaki M, Kajitani N, Nishishita S, Sarai K, Hirota D, Sato C, Ogawa D, Makino H: Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes. Diabetologia 2011; 54: 965-978.
12. Kedees MH, Grigoryan M, Guz Y, Teitelman G: Differential expression of glucagon and glucagon-like peptide-1 receptors in mouse pancreatic - and - cells in two models of - cell hyperplasia. Mol Cell Endocrinol 2009; 311: 69-76.
13. Park CW, Kim HW, Ko SH, Lim JH, Ryu GR, Chung HW, Han SW, Shin SJ, Bang BK, Breyer MD, Chang YS: Long-term treatment of glucagon-like peptide-1 analog exendin-4 ameliorates diabetic nephropathy through improving metabolic anomalies in db/db mice. J Am Soc Nephrol 2007; 18: 1227-1238.
14. Obata K, Iwata K, Ichida T, Inoue K, Matsumoto E, Muragaki Y, Ooshima A: One-step sandwich enzyme immunoassay for human type IV collagen using monoclonal antibodies. Clin Chim Acta 1989; 181: 293-303.
15. Sthaneshwar P, Chan SP: Urinary type IV collagen levels in diabetes mellitus. Malays J Pathol 2010; 32: 43-47.
16. Eng J: Exendin peptides. Mt Sinai J Med 1992; 59: 147-149.
17. Underwood CR, Garibay P, Knudsen LB, Hastrup S, Peters GH, Rudolph R, Reedtz-Runge S: Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor. J Biol Chem 2010; 285: 723-730.
18. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, Perfetti R: Glucagonlike peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397-4408.
19. Abu-Hamdah R, Rabiee A, Meneilly GS, Shannon RP, Andersen DK, Elahi D: Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J Clin Endocrinol Metab 2009; 94: 1843-1852.
20. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC: Effects of exenatide plus rosiglitazone on - cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care 2010; 33: 951-957.
21. Eknoyan G: Obesity, diabetes, and chronic kidney disease. Curr Diab Rep 2007; 7: 449-453.
22. Wiederkehr M, Toto R, Fenves AZ, Ram CV: Hypertension and the kidney. Semin Nephrol 2005; 25: 236-245.
23. Hirata K, Kume S, Araki S, Sakaguchi M, Chin-Kanasaki M, Isshiki K, Sugimoto T, Nishiyama A, Koya D, Haneda M, Kashiwagi A, Uzu T: Exendin-4 has an antihypertensive effect in salt-sensitive mice model. Biochem Biophys Res Commun 2009; 380: 44-49.
24. Ellis D, Forrest KY, Erbey J, Orchard TJ: Urinary measurement of transforming growth factor - and type IV collagen as new markers of renal injury: Application in diabetic nephropathy. Clin Chem 1998; 44: 950-956.
25. Ishibashi Y, Nishino Y, Matsui T, Takeuchi M, Yamagishi SI: Glucagon-like peptide-1 suppresses advanced glycation end productinduced monocyte chemoattractant protein-1 expression in mesangial cells by reducing advanced glycation end product receptor level. Metabolism 2011; 60: 1271-1277.